PHARMACY

AstraZeneca announces plans to provide more company information on its Web site

BY Drew Buono

WILMINGTON, Del. AstraZeneca has announced plans to make its U.S. business more public, by sharing more company information and to make other information more noticeable on its Web site. The company is performing this in an attempt to better inform the public about how it conducts its business and how it helps patients through research and support for external organizations.

The information that will be posted includes: policy positions, political contributions, medical education grants, contributions to nonprofit organizations and post-marketing study commitments and will make clinical trials and compliance programs more visible.

Currently, AstraZeneca posts details of its clinical trials and compliance programs and its policy positions. In the second quarter of this year, it plans on adding political contributions in accord with its Federal Election Commission filings. By the fall of this year, third-party contributions, medical education grants and post-marketing study commitments will be featured on the site.

“We believe in providing information to the public about our company, our products and how we do business as part of our commitment to improving patient health and corporate responsibility,” said David Nicoli, vice president of corporate affairs at AstraZeneca. “This important information will help the public better understand significant aspects of our business.”

AstraZeneca’s U.S. Web site address is, www.astrazeneca-us.com.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

CDC study finds 1-in-4 teen girls has an STD; recommends screening, vaccination, education

BY Adam Kraemer

CHICAGO An alarming number of teenage girls has a sexually transmitted disease, according to a recent study by the Centers for Disease Control and Prevention: slightly more than one-quarter.

The overall rate of STDs among the 838 girls in the study was 26 percent, translating to more than 3 million nationwide, the Associated Press reported.

About half of the girls surveyed admitted to having sex—though their definitions of what that consisted of varied—and among those, the number with an STD climbed to 40 percent.

The new study, by CDC researcher Sara Forhan, actually relied on slightly older data from nationally representative records on girls ages 14 to 19 who participated in a 2003-04 government health survey. The director of the CDC’s division of STD prevention, John Douglas, has stated that the data still likely reflect current prevalence rates.

The teens were tested for human papillomavirus, chlamydia, trichomoniasis and genital herpes. HPV prevalence was significantly higher than the others, accounting for 18 percent of the STD cases, with the others all reporting a rate below 5 percent.

Many doctors feel that the prevalence of STDs is due, in part, to the government’s abstinence-only policy in sex education. Teens, they say, are simply not getting the information that would enable them to protect against these diseases.

The CDC recommends that teens get routinely screened and educated about prevention. Kevin Fenton, the CDC’s Director for the National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention said given the dangers of some STDs, “screening, vaccination and other prevention strategies for sexually active women are among our highest public health priorities.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

U.S. prescription sales grew modestly to $286.5 billion in 2007

BY Adam Kraemer

NORWALK, Conn. IMS Health today released its annual U.S. Pharmaceutical Market Performance Review, reporting that overall sales growth in the U.S. prescription market moderated to 3.8 percent in 2007, compared with growth of more than 8 percent in 2006.

Total U.S. prescription sales reached $286.5 billion, with slower sales growth resulting from loss of exclusivity of branded medicines, fewer new product approvals, the leveling of year-over-year growth from the Medicare Part D program and the impact of safety issues, IMS Health reported. The 2006 growth was an anomaly, in other words, due to the implementation of Medicare Part D, but 2007’s slowing growth rate is a continued trend that began in 2001, according to the report

Compared with a 4.6 percent growth in 2006, total U.S. dispensed prescription volume grew at a 2.8 percent pace. The top five therapeutic categories—antidepressants, lipid regulators, codeine & combination pain medications, ace inhibitors and beta blockers—continued to lead the market in terms of prescription utilization.

“In 2007, the U.S. pharmaceutical market experienced its lowest growth rate since 1961,” said IMS’s Murray Aitken, senior vice president of Healthcare Insight. “Last year, we saw a continuing shift away from primary care classes to biotech and specialist-driven therapies, which grew at a 9 percent and 10 percent pace, respectively. Among the leading therapy classes, oncology drugs continued their rapid growth, at 14 percent—the result of innovative new medicines, expanded indications and accelerated uptake of products to fill unmet needs.”

Sales of lipid regulators declined by 15.4 percent year-over-year, though continued to represent the largest therapy class in the nation, with prescription sales of $18.4 billion. Proton pump inhibitors ranked second, with prescription sales of $14.1 billion and growth of 2.8 percent. Antipsychotics replaced antidepressants as the third-largest therapeutic class in 2007, with prescription sales growth of 12.1 percent to $13.1 billion. 

The IMS report forecasts compound annual pharmaceutical sales growth through 2012 of 3 percent to 6 percent, based on predicted loss of exclusivity in major therapy areas, new specialist-driven products, greater levels of therapeutic substitution, and greater awareness and focus on safety issues.

“We will see additional lower-cost treatment options for many patients, while new and innovative therapies are delivered to specific patient groups, such as those suffering with cancer. Safety issues will be closely monitored and are likely to bring added caution to the market over the next several years,” said Aitken.

More information can be found at www.imshealth.com/media.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?